Scope and Claims Analysis for U.S. Patent 12,617,775: Dihydrate Form, Process-by-Catalyst, and Composition Protection
U.S. Patent 12,617,775 is drafted to secure exclusivity around a specific crystalline dihydrate solid form (Formula II) and to broaden enforceability through (i) a multi-step synthetic sequence using defined catalyst classes and named palladium catalyst embodiments, and (ii) a pharmaceutical composition containing that dihydrate. The strongest infringement hook is typically claim 1 (product-of-process tightly tied to stepwise catalysis). The enforceable claim set also includes composition coverage (claim 2) and multiple catalyst-specific subclaims (claims 3-8), which are designed to capture design-arounds that swap catalysts within a palladium family.
What does US 12,617,775 claim 1 cover: dihydrate Form of Formula (II) with catalyst-defined process steps?
Claim 1 is a “dihydrate Form of the compound of Formula (II)” defined by a process chain with two distinct catalytic steps and a final amination using isopropylamine.
Key structural scope elements (claim construction drivers)
-
Product identity
- The claimed subject matter is the dihydrate form of the compound of Formula (II).
- The dihydrate status is central. Even if the chemical core equals Formula (II), the claim requires the dihydrate form.
-
Process-defined formation
- The dihydrate is “prepared by” reacting:
- Formula (IX) with Formula (XII) in the presence of a first catalyst to produce Formula (IV).
- Then reacting Formula (IV) with a reagent “represented by:” (the user’s excerpt omits the structural content after “represented by:”). The claim text indicates this reaction occurs in the presence of a second catalyst, producing Formula (III).
- Finally reacting Formula (III) with isopropylamine to produce Formula (II).
-
Two catalyst-controlled steps
- Both the first and second steps are catalyzed and each catalyst is constrained to a palladium catalyst in dependent claims (claims 3-8).
- Claim 1, as provided, does not specify the catalyst identity, but dependent claims do. Practically, enforcement leverage expands because accused processes that use palladium catalysts can fall into narrower claims even if the broad catalyst language is contested.
What “product-by-process” means here in practice
Although claim 1 reads like a product claim, it is anchored to a preparation method. That structure is commonly used when:
- the product is a polymorph/solvate/ hydrate (here, a dihydrate), and
- the intrinsic characterization alone may not be sufficiently unique for broad direct product claims, so the drafter uses the preparation route to establish specificity.
For infringement, the factual question often becomes whether the accused solid is the same dihydrate (same crystal form) and whether it is prepared by a materially similar route. The dependent catalyst claims narrow that route further.
How broad is the catalyst scope in claim 1 vs dependent claims 3-8?
Claim 1: catalysis exists in two steps, but the provided excerpt does not limit the catalyst class in claim 1 itself.
Claims 3-5: the first catalyst is palladium, with specific listed catalysts.
Claims 6-8: the second catalyst is palladium with the same list and includes the same Pd(PPh3)4 embodiment.
Dependent claim catalyst list (enumerated palladium catalysts)
The palladium catalysts enumerated are:
- Pd(PPh3)4
- Pd(OAc)2/SPhos
- Pd(dppf)Cl2
- Pd(dppf)Cl2·DCM
- XPhos Pd G2
- Pd2(dba)3
Dependent claims also create explicit “winner” embodiments:
- Claim 5: first catalyst is Pd(PPh3)4
- Claim 8: second catalyst is Pd(PPh3)4
Enforcement implications of the enumeration
Enumerating catalysts helps the patentee in two ways:
-
Design-around containment
- Many process variants in this chemical space use palladium complexes with common ligands. By listing specific catalysts, the patent can catch common substitutions inside the same mechanistic family.
-
Claim stacking
- If an accused process uses palladium catalysts but not the exact same complex, it may still fall under claim 3 or 6 (“palladium catalyst”), depending on how strictly claim 1 defines the catalyst and how courts construe those terms.
What does claim 2 add: pharmaceutical composition protection for the dihydrate
Claim 2 covers a pharmaceutical composition comprising:
- the dihydrate of claim 1, plus
- a pharmaceutically acceptable excipient.
How claim 2 typically expands patent leverage
Composition claims often capture:
- formulated drug product,
- intermediate manufacturing that includes excipient blends (depending on how infringement is alleged),
- and “salt/form” substitution strategies if the solid form is preserved.
The breadth is limited by the requirement that the composition includes the dihydrate form (not anhydrous, monohydrate, or another polymorph unless those also meet the dihydrate definition).
How does the isopropylamine final step narrow claim scope?
The final step in claim 1 is:
- reacting Formula (III) with isopropylamine to prepare Formula (II).
This is a strong narrowing element. Many chemical design-arounds try to replace the amine source (e.g., different alkylamines or protected amine equivalents). Because the claim requires isopropylamine (as written), an accused process using a different amine feedstock or a different deprotection/aminolysis route may fall outside claim 1 unless it can still be argued to use isopropylamine functionally in the route.
What types of “adjacent” claims are missing in this set, and what that implies for landscape analysis
Based solely on the provided claims (1-8), the patent appears focused on:
- Form: dihydrate of Formula (II)
- Process: two catalytic steps to reach Formula (IV) and Formula (III)
- Final installation: isopropylamine
- Use in product: pharmaceutical composition
What is not present in the excerpt:
- explicit particle size, XRPD peaks, DSC profiles, or other characterization-based limitations for the dihydrate
- explicit therapeutic indications (method-of-use)
- explicit formulation compositions beyond excipient inclusion
- explicit manufacturing parameters (temperatures, solvent systems, water content control)
- explicit salt forms (other than dihydrate)
This absence matters for freedom-to-operate thinking: if competitor products use a different hydrate/solvate form or a different synthetic endpoint, the claim coverage may be narrower than a more fully characterized polymorph patent. That said, the explicit catalysts in dependent claims increase the chance of catching “route-faithful” manufacturing.
How strong are claims 3-8 for stopping catalyst substitutions and route changes?
Claims 3-8 are structured as a claim ladder. The list of catalysts creates several distinct infringement pathways:
- A process using palladium at the first step can satisfy claim 3.
- If that palladium is one of the enumerated catalysts, claims 4 and 5 become available.
- A process using palladium at the second step can satisfy claim 6.
- If that palladium matches an enumerated catalyst, claims 7 and 8 become available.
Design-around risk: “move the palladium” or “change the complex”
If a competitor alters:
- first-step catalyst only, they may avoid claim 3/4/5 but still be exposed under claim 6/7/8 for the second step.
- second-step catalyst only, the reverse holds.
- both steps, they may reduce the odds of matching any dependent claims, but claim 1 still requires the process sequence with “in the presence of a first catalyst” and “in the presence of a second catalyst” (as written in the excerpt). So total escape requires either:
- eliminating catalyst usage (unlikely for industrial feasibility in similar couplings), or
- using a non-catalytic alternative process that is structurally equivalent in outcome, which is often hard.
Claim mapping framework: what elements must an accused process or product meet?
A. Product/material mapping
- Does the accused API solid correspond to the dihydrate of Formula (II)?
- Does the accused drug product contain that dihydrate?
B. Route mapping (for process-by-product infringement theories)
- Is the dihydrate “prepared by” the claimed sequence:
- Formula (IX) + Formula (XII) with a first catalyst → Formula (IV)
- Formula (IV) + (reagent represented by missing structural placeholder) with a second catalyst → Formula (III)
- Formula (III) + isopropylamine → Formula (II)
- Are the catalysts palladium in the relevant steps and do they match the enumerated complexes (claims 3-8)?
This mapping drives litigation posture: if the competitor’s manufacturing route uses different intermediates or amine chemistry, claim 1 becomes harder to meet.
What patent landscape questions does this claim set support (and what can be concluded from the claim text)
Even without external bibliographic data (filing dates, assignees, related continuations, cited prior art), the claim structure signals the usual landscape pattern for hydrate/form protection:
-
Likely family coverage
- This patent is likely part of a broader chemical family that covers:
- the core compound (Formula II),
- earlier intermediates (Formulas III/IV/IX/XII),
- and other solid forms (solvates/polymorphs).
-
Potential “improvement” strategy
- The dihydrate claim suggests a crystallization/formulation or purification discovery. Such families often have competing forms patents (anhydrous, monohydrate, other solvates) filed by the same assignee.
-
Litigation leverage
- If competitors introduce a generic, challengers often attempt to:
- sell a different crystal form,
- sell a different salt,
- or match the API but use a different manufacturing route.
- The catalyst-specific dependent claims and the isopropylamine step are intended to close route-based defenses.
Key takeaways
- U.S. 12,617,775 is a dihydrate (Formula II) patent where the core scope is anchored to claim 1’s process-by-product sequence with two catalyst-driven transformations and a final isopropylamine step.
- Claim 2 adds direct composition coverage for any pharmaceutical formulation containing the dihydrate plus standard excipients.
- Claims 3-8 are strategically important: they narrow infringement risk by tying both catalytic steps to palladium and explicitly enumerating common palladium complexes, including Pd(PPh3)4 as a dedicated embodiment.
- Practical enforceability hinges on whether competitors’ API solid form truly matches the dihydrate and whether their manufacturing route uses the same catalytic framework and isopropylamine chemistry.
FAQs
1) Can a competitor avoid US 12,617,775 by using a different palladium catalyst?
Not if the substituted palladium catalyst still matches the enumerated complexes in claims 4 and 7, or if it remains a palladium catalyst within the scope of claims 3 and 6 for the relevant step.
2) Does US 12,617,775 cover the dihydrate only as an API or also in formulated products?
Both, via claim 1 for the dihydrate itself and claim 2 for pharmaceutical compositions containing the dihydrate with excipients.
3) What is the most important narrowing element besides the dihydrate designation?
The final step requiring isopropylamine to form Formula (II).
4) What manufacturing changes are most likely to reduce infringement risk?
Changing the route such that the sequence does not produce the claimed intermediates under the claimed catalytic conditions, or using amine chemistry that is not based on isopropylamine as recited in the claim chain.
5) Why are catalyst-specific dependent claims valuable for litigation?
They create multiple independent claim targets tied to commonly used palladium catalysts, reducing the effectiveness of partial route substitutions that would otherwise avoid the broad catalyst language.
References
- U.S. Patent 12,617,775 (claims as provided by user excerpt).
